UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050476
Receipt number R000057492
Scientific Title A Prospective Observational Study of patients who switched from SGLT2 inhibitor tablets to luseogliflozin OD film formulation in terms of feeling, Efficacy and Safety of taking the medicine.
Date of disclosure of the study information 2023/04/01
Last modified on 2023/03/02 21:35:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Observational Study of patients who switched from SGLT2 inhibitor tablets to luseogliflozin OD film formulation in terms of feeling, Efficacy and Safety of taking the medicine.

Acronym

A Survey of feeling of taking Lusefi OD film formulation

Scientific Title

A Prospective Observational Study of patients who switched from SGLT2 inhibitor tablets to luseogliflozin OD film formulation in terms of feeling, Efficacy and Safety of taking the medicine.

Scientific Title:Acronym

A Survey of feeling of taking Lusefi OD film formulation

Region

Japan


Condition

Condition

Type 2 Diabetes Mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of switching the dosage form of SGLT2 inhibitors from tablets to OD films on the feeling of taking the drug, adherence, weight, liver enzymes and glycemic control status (1.5-AG, glycoalbumin, HbA1c).

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1) OHA-Q ver.2 after 1 month of switching
2) The change from baseline in HbA1c after 6 months of switching

Key secondary outcomes

1) Change over time from baseline in HbA1c up to 6 months after the switch
2) Change over time in the following items a) to d) up to 6 months after the switch
a) 1.5-AG
b) GA
c) Liver enzymes(AST,ALT,GGT)
d) Weight
3) Adherence(Pill Counting)
4) Stratified analysis of the following a) to c)
a) By each SGLT2 inhibitor
b) By patient background
c) By medication adherence
5) OHA-Q ver.2 after 6 months of switching


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients with type 2 diabetes mellitus who have been switched from Lusefi tablets to Lusefi OD film, or from other SGLT-2 inhibitors to Lusefi OD film.
(2) Patients who have consented to the purpose of this survey

Key exclusion criteria

(1) Patients who changed from Lusefi OD film to Lusefi tablets or other SGLT-2 inhibitor tablets during the study period.
(2) Patients who have changed or added other hypoglycemic drugs.
(3) Patients who have their medications packaged in a single package.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Hideki
Middle name
Last name Sugawara

Organization

Mittel Pharmacy Kaisei

Division name

Kaisei

Zip code

963-8041

Address

6-192-1,Kaisei,Koriyama,Fukushima

TEL

024-935-7336

Email

h.sugawara@mittel.jp


Public contact

Name of contact person

1st name Hiroaki
Middle name
Last name Seino

Organization

Seino internal Medicine Clinic

Division name

internal Medicine

Zip code

963-8041

Address

6-192-2,Kaisei,Koriyama,Fukushima

TEL

024-983-1024

Homepage URL


Email

info@seino-clinic.jp


Sponsor or person

Institute

Seino internal Medicine Clinic

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Mittel Pharmacy Kaisei

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Seino internal Medicine Clinic Clinical Secretariat

Address

6-192-2,Kaisei,Koriyama,Fukushima

Tel

024-983-1024

Email

kn7jh5@bma.biglobe.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 08 Month 15 Day

Date of IRB


Anticipated trial start date

2023 Year 04 Month 01 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

1) Change over time from baseline in HbA1c up to 6 months after the switch
2) Change over time in the following items a) to d) up to 6 months after the switch
a) 1.5-AG
b) GA
c) Liver enzymes(AST,ALT,GGT)
d) Weight
3) Adherence(Pill Counting)
4) Stratified analysis of the following a) to c)
a) By each SGLT2 inhibitor
b) By patient background
c) By medication adherence
5) OHA-Q ver.2 after 6 months of switching


Management information

Registered date

2023 Year 03 Month 02 Day

Last modified on

2023 Year 03 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057492


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name